The diagnostic and prognostic value of ProGRP in lung cancer.


AIM To investigate the diagnostic and prognostic significance of pro-gastrin-releasing peptide (ProGRP) in non-small cell (NSCLC) and small cell lung cancer (SCLC) and compare this marker with other known serum markers in lung cancer. PATIENTS AND METHODS Serum levels of ProGRP, neuron-specific enolase (NSE), CYFRA 21-1 and carcinoembryonic antigen (CEA) were measured in 37 patients with benign pulmonary disease (BPD), 88 with advanced NSCLC and 37 with SCLC. RESULTS The ProGRP assay showed a better clinical performance than that of NSE in discriminating between SCLC and BPD or NSCLC, especially at specificity higher than 90%. ProGRP and NSE sensitivity in SCLC at 95% specificity versus the BPD group was 78.4% and 48.6%, (p=0.001) and at 97.7% specificity versus NSCLC, 75.7% and 37.8%, respectively (p=0.001). A significant association of low ProGRP levels with high-grade NSCLC tumors was found (p=0.002). A univariate analysis showed a significant association of ProGRP with survival both in NSCLC and SCLC (p=0.03 and p=0.04, respectively). In multivariate analysis, performance status (PS) and CYFRA 21-1 in NSCLC, and PS, CYFRA 21-1 and serum lactic dehydrogenase in SCLC were found as significant variables with an independent impact on survival. CONCLUSION ProGRP is a useful marker in SCLC, with diagnostic performance better than that of NSE and demonstrating association with survival in NSCLC and SCLC limited to univariate analysis.

Citations per Year

248 Citations

Semantic Scholar estimates that this publication has 248 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Nisman2009TheDA, title={The diagnostic and prognostic value of ProGRP in lung cancer.}, author={Benjamin Nisman and Haim Biran and N. Ramu and Norman I Heching and Vivian Barak and Tamar Peretz}, journal={Anticancer research}, year={2009}, volume={29 11}, pages={4827-32} }